Natera (NASDAQ:NTRA) received a $45.00 price target from investment analysts at Piper Jaffray Companies in a research note issued on Friday, TipRanks reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Piper Jaffray Companies’ price objective would indicate a potential upside of 17.46% from the stock’s current price.
NTRA has been the subject of several other research reports. BidaskClub upgraded shares of Natera from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 8th. Canaccord Genuity reiterated a “buy” rating and set a $44.00 target price on shares of Natera in a research report on Wednesday, September 25th. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday, August 9th. Craig Hallum upped their target price on shares of Natera from $29.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, ValuEngine cut shares of Natera from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $36.00.
NASDAQ:NTRA traded up $1.25 during trading hours on Friday, hitting $38.31. 24,163 shares of the stock were exchanged, compared to its average volume of 609,406. The company’s 50 day moving average is $33.11 and its two-hundred day moving average is $26.13. Natera has a twelve month low of $11.08 and a twelve month high of $37.42. The company has a quick ratio of 2.42, a current ratio of 2.54 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $2.50 billion, a P/E ratio of -17.78 and a beta of 1.42.
In related news, CEO Steven Leonard Chapman sold 98,996 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $33.00, for a total value of $3,266,868.00. Following the completion of the sale, the chief executive officer now owns 20,061 shares in the company, valued at approximately $662,013. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Jonathan Sheena sold 250,000 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $31.37, for a total transaction of $7,842,500.00. Following the completion of the sale, the insider now owns 364,645 shares of the company’s stock, valued at approximately $11,438,913.65. The disclosure for this sale can be found here. Insiders have sold a total of 438,799 shares of company stock valued at $13,882,942 in the last quarter. Corporate insiders own 9.29% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. increased its position in shares of Natera by 1.7% in the 2nd quarter. Macquarie Group Ltd. now owns 2,262,808 shares of the medical research company’s stock valued at $62,408,000 after buying an additional 36,939 shares in the last quarter. River & Mercantile Asset Management LLP bought a new stake in shares of Natera in the 2nd quarter valued at $2,843,000. Orbimed Advisors LLC increased its position in shares of Natera by 199.2% in the 2nd quarter. Orbimed Advisors LLC now owns 3,224,328 shares of the medical research company’s stock valued at $88,927,000 after buying an additional 2,146,742 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Natera in the 2nd quarter valued at $401,000. Finally, Royal Bank of Canada increased its position in shares of Natera by 1,097.7% in the 2nd quarter. Royal Bank of Canada now owns 46,518 shares of the medical research company’s stock valued at $1,284,000 after buying an additional 42,634 shares in the last quarter. Institutional investors and hedge funds own 94.95% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: Quantitative Easing
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.